Database

Startups

Main Industry
Health Care
Main Product/Service
AcadeMab’s pipeline includes AM‑928, an anti‑EpCAM monoclonal antibody for solid tumors; AM‑168, an anti‑HER3 antibody for patients resistant to EGFR or HER2 therapies; and SB‑001, a monoclonal antibody targeting COVID‑19.
In parallel, AcadeMab is develo
Founded Year
2020
Unified Business No.
83769127
Status
Active
Number of Employees
0
Total Paid-in Capital
503,310,000 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
AcadeMab Biomedical Inc., founded in 2020, is a Taiwan‑based biotech company dedicated to novel antibody therapeutics and mRNA vaccine development. By integrating advanced antibody discovery platforms with mRNA-LNP technology, AcadeMab aims to tackle unme



More ↓

Similar Companies

HONYA MEDICAL CO., LTD.

1. Cell Therapy
2. Clinical trial
3. MCRcI®
4. MiSaver®

TRUST BIO-SONICS INC.

1. Ultrasound Imaging Agents
2. Ultrasound-Mediated Targeted Delivery

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre